MedTrace Logo

A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects

NCT01173536 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2017-02-17

No results posted yet for this study

Summary

This is a Phase I, single-center, three-arm, randomized, double-blind, active- and placebo-controlled study to investigate the effect of GDC-0449 on the QT/QTc interval in healthy female subjects of non-childbearing potential.

Conditions

  • Healthy Volunteer

Interventions

DRUG

GDC-0449

Oral repeating dose

DRUG

moxifloxacin

Oral single dose

DRUG

placebo

Oral repeating dose

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Jean Ayache, M.D. · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-25
Primary Completion
2011-03-18
Completion
2011-03-18

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01173536 on ClinicalTrials.gov